• Explore /
  • Poster
  • / Perioperative lenvatinib combined with tislelizumab plus transcatheter arterial chemoembolization in resectable hepatocellular carcinoma with high-risk of recurrence: A prospective, single-arm, phase 2 trial.

Perioperative lenvatinib combined with tislelizumab plus transcatheter arterial chemoembolization in resectable hepatocellular carcinoma with high-risk of recurrence: A prospective, single-arm, phase 2 trial.

Abstract Poster

Authors

null

Jia-Yi Wu

Fujian Provincial Hospital, Fuzhou, China

Jia-Yi Wu , Yang-Kai Fu , Tianfu Wen , Shuang-Jia Wang , Jiafei Chen , Zhibo Zhang , Chongyuan Liu , Wei Wang , Lu Fang , Zhong Tang , Yufeng Chen , Maolin Yan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

ChiCTR2100048249

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 503)

DOI

10.1200/JCO.2024.42.3_suppl.503

Abstract #

503

Poster Bd #

D10

Abstract Disclosures

Similar Posters

First Author: Bin Zhang

First Author: Xiang Nong

First Author: Hongyu Pan

First Author: Jiwei Huang